Utah Medical Products financials
$74.95+0.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.5M | $40.9M | $50.2M | $52.3M | $49.1M | $42.2M | $46.9M | $42.0M | $41.4M | $39.3M |
| Gross profit | $22.0M | $24.1M | $30.0M | $32.2M | $30.9M | $25.5M | $29.5M | $26.3M | $26.4M | $23.7M |
| Gross margin | 57.1% | 59.0% | 59.8% | 61.6% | 63.0% | 60.6% | 62.8% | 62.6% | 63.7% | 60.3% |
| Operating income | $11.4M | $13.6M | $16.8M | $19.8M | $18.9M | $13.7M | $17.6M | $18.7M | $19.0M | $16.2M |
| Net income | $11.3M | $13.9M | $16.6M | $16.5M | $14.8M | $10.8M | $14.7M | $18.6M | $8.5M | $12.1M |
| Net margin | 29.3% | 33.9% | 33.1% | 31.5% | 30.1% | 25.6% | 31.4% | 44.2% | 20.5% | 30.9% |
| Diluted EPS | $3.48 | $3.96 | $4.57 | $4.52 | $4.04 | $2.94 | $3.94 | $4.95 | $2.28 | $3.22 |
| EBITDA | $14.4M | $16.4M | $23.1M | $26.8M | $26.2M | $20.9M | $24.5M | $21.7M | $21.8M | $19.0M |
| Operating cash flow | $14.7M | $14.8M | $22.3M | $21.1M | $21.2M | $20.1M | $17.1M | $16.8M | $16.9M | $14.5M |
| Free cash flow | $14.3M | $14.6M | $21.6M | $20.3M | $20.7M | $19.3M | $16.5M | $16.4M | $15.3M | $11.2M |
| Diluted shares | 3.2M | 3.5M | 3.6M | 3.6M | 3.7M | 3.7M | 3.7M | 3.7M | 3.7M | 3.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $85.8M | $83.0M | $92.9M | $75.1M | $61.0M | $51.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $282.0K | $295.0K | $0.00 | $0.00 | $0.00 |
| Total assets | $122.5M | $122.5M | $135.5M | $123.9M | $115.6M | $111.7M |
| Total liabilities | $3.3M | $5.1M | $7.1M | $9.6M | $8.5M | $8.9M |
| Shareholders' equity | $119.3M | $117.4M | $128.3M | $114.3M | $107.1M | $102.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology